# Journal of **AESTHETIC** NURSING

EDITOR: Jasmine Callaghan jasmine.callaghan@markallengroup.com CIRCULATION DIRECTOR: Sally Boettcher PRODUCTION MANAGER: Kyri Apostolou PUBLISHING DIRECTOR: Andrew Iafrati andrew.iafrati@markallengroup.com ASSOCIATE PUBLISHER: Sophie Gardner COMMERCIAL MANAGER: Victoria Gould victoria.gould@markallengroup.com CHIEF EXECUTIVE OFFICER: Ben Allen MANAGING DIRECTOR: Anthony Kerr

### **EDITORIAL BOARD**

CONSULTANT EDITOR Cheryl Barton Aesthetic Nurse and Managing Director, Aesthetika, Sheffield EDITORIAL BOARD Clare Amrani Independent Nurse Prescriber, Iuvenis Aesthetics, Harrow Anna Baker Asthetic Nurse, Dalvi Humzah Aesthetic Clinical Training Courses, London and Sussex Julie Brackenbury Aesthetic Nurse, Bristol Annie Cartwright Advanced Aesthetic Nurse Practitioner and Director, Shin and Face Clinics, Cardiff Leslie Fletcher Aesthetic Nurse Specialist, US Trudy Friedman Aesthetic Nurse Practitioner, Aesthetic Skin Centre, London Isabel Lavers Dermatology Nurse Specialist, Salford Royal NHS Foundation Trust Alexandra Mills Haq Director and aesthetic nurse, AM Aesthetics, London and Northern Ireland Enma Soos Clinical and Managing Director,

The Women's Health Clinic, London

#### UK PERSONAL SUBSCRIPTION RATES

(11111)	
Quarterly Direct Debit	£31
Annual Direct Debit	£123
Annual Credit Card	£129
Two year Annual Credit Card	£219
Three year Annual Credit Card	£310

Subscribe online: www.magsubscriptions.com Subscribe by phone: +44 (0) 1722 716997

Contact institutions@markallengroup.com for institutional pricing

# MA Healthcare Mark Allen

www.markallengroup.com

The Journal of Aesthetic Nursing is published by MA Healthcare Ltd, St Jude's Church, Dulwich Road, London, SE24 OPB Tel: +44 (0)20 7738 5454 Website: www.aestheticnursing.co.uk

## MAG ONLINE LIBRARY

© MA Healthcare Ltd, 2023. All rights reserved. No part of *Journal* of Aesthetic Nursing may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording, or otherwise without prior written permission of the Publishing Director.

Please read our privacy policy, by visiting http://privacypolicy. markallengroup.com. This will explain how we process, use and safeguard your data.

The views expressed do not necessarily represent those of the editor or the *Journal of Aesthetic Nursing*. Advertisements in the journal do not imply endorsement of the products or services advertised.

ISSN 2050-3717

Printed by Pensord Press Ltd, Blackwood, NP12 2YA



Ltd

When you have finished with this magazine please recycle it.

# Anti-ageing drugs

ince the theory of ageing as a process in which oxidative stress led to accumulation of damage of the cellular environment over time, first proposed by Harman (1956), we have seen an exponential expansion in our understanding of the ageing process. Many advances have contributed to our understanding of the ageing process and how to mitigate its effects. Some important milestones have led to a leap in our understanding

and these are briefly discussed below. A more expansive explanation of an area that will no doubt lead to the bench-to-bedside transition that we seek as clinicians is provided by Kirkwood and Austad (2000) and by López-Otín et al. (2013).

- Cellular senescence: This phenomenon, whereby cells stop dividing and contribute to the ageing process, has provided a foundation for understanding ageing at the cellular level.
- Discovery of telomeres: These are the protective end caps of chromosomes, and how they shorten as cells divide has shed light on how cellular ageing occurs. Telomere extension refers to the prolongation and preservation of the protective end caps of chromosomes that shorten as cells divide, contributing to cellular ageing. Drugs that extend telomeres are being developed to delay cellular ageing. Several drugs have been shown to affect telomerase activity. For instance, epicatechins, which are flavonoids found in green tea, have been shown to activate telomerase in vitro, with some studies suggesting that they may have potential as a telomere-protective agent.
- Advances in stem cell therapy: These have the potential to replace damaged or ageing cells and improve tissue function, which could help delay the ageing process.
- Lifestyle interventions: A growing body of evidence suggests that lifestyle interventions, such as diet (intermittent fasting and altered nutrient sensing) and exercise, can improve health and potentially delay the ageing process by reducing oxidative stress and inflammation.
- Development of anti-ageing drugs: These target the underlying mechanisms of ageing, such as mTOR inhibitors and senolytics, and hold promise for delaying the ageing process.
  I. mTOR inhibitors: These drugs target the mTOR pathway, which regulates cell growth and division, and are being developed to delay the ageing process and improve longevity.
  - 2. Senolytics: These drugs target senescent cells, cells that have stopped dividing and are contributing to ageing and disease.
  - 3. NAD+ boosters: NAD<sup>+</sup> (nicotinamide adenine dinucleotide) is a molecule which is involved in various cellular processes but declines with age.
  - 4. Sirtuin activators: Sirtuins are a family of enzymes that regulate cellular processes and are involved in ageing. Sirtuin activators are being analysed and created to improve cellular function and delay ageing. Sirtuins are named after the yeast gene Silent Information Regulator 2 (SIRT2), which was the first sirtuin to be identified. There are seven different



Alexandra Mills Director and Aesthetic Nurse, AM Aesthetics, London and Northern Ireland sirtuins in mammals (SIRTI-7), each with distinct functions and tissue distributions. Some sirtuins have been linked to longevity in various species, and several sirtuin activators are being developed as potential therapies for various diseases and age-related conditions.

Anti-ageing medicine will be a defining area both in mainstream medicine and medical aesthetics as we see more developments over the coming decade, with an estimated doubling of the valuation of this area in terms of revenue from \$22.5 to \$44.5 billion USD.

## References

Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol. 1956; 11(3), 298–300. https://doi.org/10.1093/geronj/11.3.298 Kirkwood TB, Austad SN. Why do we age? Nature. 2000; 408(6809), 233–238. https://doi.org/10.1038/35041682

López-Otín C, Blasco MA, Partridge L et al. The hallmarks of aging. Cell. 2013; 153(6), 1194–1217. https://doi.org/10.1016/j.cell.2013.05.039